𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus

✍ Scribed by A. Johnsson; Peter Höglund; Anders Grubb; Eva Cavallin-Sta˚hl

Publisher
Springer
Year
1996
Tongue
English
Weight
781 KB
Volume
39
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Paclitaxel, cisplatin, and 5-fluorouraci
Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck
✍ Maha Hussain; Shirish Gadgeel; Omer Kucuk; Wei Du; Walter Salwen; John Ensley 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 3 views

## BACKGROUND. The combination of cisplatin and 5-flurouracil (5-FU) is considered standard therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Paclitaxel has exhibited single-agent activity in patients with this disease. The authors conducted thi

Efficacy of neck treatment in patients w
Efficacy of neck treatment in patients with head and neck squamous cell carcinoma
✍ Gabriela Buck; Pia Huguenin; Sandro J. Stoeckli 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views

## Abstract ## Background. Treatment of head and neck squamous cell carcinoma (HNSCC) addresses the primary tumor and the lymphatic drainage. Modalities for the neck are neck dissection and/or radiation therapy. In most cases, the neck is treated by the modality that seems more appropriate for the

Pharmacodynamic evaluation of temsirolim
Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma
✍ Oleksandr Ekshyyan; Glenn M. Mills; Timothy Lian; Nazanin Amirghahari; Xiaohua R 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 244 KB 👁 1 views

## Abstract ## Background: Activation of the mammalian target of rapamycin (mTOR) pathway in surgical margins of head and neck squamous cell carcinoma (HNSCC) is a predictor of recurrence and patients with minimal residual disease may benefit from adjuvant therapy with temsirolimus, an mTOR inhibi

Vinblastine, bleomycin and cisplatin for
Vinblastine, bleomycin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck
✍ David J. Perry; Martin D. Weltz; Archie W. Brown Jr; Robert L. Henderson; Willia 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB 👁 3 views

Forty-two patients with recurrent or metastatic squamous cell carcinoma of the head and neck were treated with vinblastine, bleomycin, and cisplatin. All patients had received prior surgery, radiation or chemotherapy and all had measurable disease. Forty-five percent of the patients responded with a